CEL-SCI (CVM +4.7%) bucks the broad market’s softness, albeit on below-average volume, after reporting encouraging results from animal studies on its LEAPS COVID-19 conjugates that, it says, showed faster and “much higher than expected” antibody responses against a non-mutating region of SARS-CoV-2 after only one injection. IgG antibody response was noted within 10 days.
Animal challenge studies are next up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.